Custom Premix Selecting "Custom Premix" option means that all of the beads you have chosen will be premixed in manufacturing before the kit is sent to you.
An adenosine analog that acts as a selective, high affinity agonist for Adenosine A1 receptor (A1R) (Ki = 800 pM; 2.3 µM, 18.8 µM, and 42 nM for human A1, A2A, A2B, A3 respectively). Shown to be centrally active following systemic administration and exhibits anti-convulsive effects. Also reported to inhibit adenylate cyclase activity in rat fat cell membrane (IC50 = 33 nM). Diminishes respiratory rhythm, reduces heart rate, and enhances the activity of KATP channels. Reduces norepinephrine release by about 50% in untreated and pertussis toxin treated hearts.
Adenosine A1 Receptor Agonist II, CCPA - CAS 37739-05-2 - Calbiochem 分析证书
标题
批号
119136
参考
参考信息概述
Burgdorf, C. et al. 2005. J Cardiovasc Pharmacol.45, 1. Klotz, K. N., et al. 2000. Naunyn Schmiedebergs Arch Pharmacol. 362, 382. Mironov, S., et al. 1990. J Neurophysiol.81, 1. Monopoli, A., et al. 1994.Arzneimittelforschung.44, 1305. Concas, A., et al. 1993. J Pharmacol Exp Ther.267, 844. Lohse, M. J., et al. 1988. Nauryn Schmiedebergs Arch Pharmacol.337, 687. Coffin, V. L., et al. 1987. J Pharmacol Exp Ther.241, 76.
数据表
Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.
An adenosine analog that acts as a selective, high affinity agonist for Adenosine A1 receptor (A1R) (Ki = 800 pM; 2.3 µM, 18.8 µM, and 42 nM for human A1, A2A, A2B, A3 respectively). Shown to be centrally active following systemic administration and exhibits anti-convulsive effects. Also reported to inhibit adenylate cyclase activity in rat fat cell membrane (IC50 = 33 nM). Diminishes respiratory rhythm, reduces heart rate, and enhances the activity of KATP channels. Reduces norepinephrine release by about 50% in untreated and pertussis toxin treated hearts.
Form
White solid
Intert gas (Yes/No)
Packaged under inert gas
CAS number
37739-05-2
Chemical formula
C₁₅H₂₀ClN₅O₄
Structure formula
Purity
≥99% by HPLC
Solubility
DMSO (100 mM) or H₂O (5 mM)
Storage
Protect from light
+2°C to +8°C
Do Not Freeze
Ok to freeze
Special Instructions
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Toxicity
Standard Handling
References
Burgdorf, C. et al. 2005. J Cardiovasc Pharmacol.45, 1. Klotz, K. N., et al. 2000. Naunyn Schmiedebergs Arch Pharmacol. 362, 382. Mironov, S., et al. 1990. J Neurophysiol.81, 1. Monopoli, A., et al. 1994.Arzneimittelforschung.44, 1305. Concas, A., et al. 1993. J Pharmacol Exp Ther.267, 844. Lohse, M. J., et al. 1988. Nauryn Schmiedebergs Arch Pharmacol.337, 687. Coffin, V. L., et al. 1987. J Pharmacol Exp Ther.241, 76.